Journal of Cardiovascular Translational Research

, Volume 6, Issue 5, pp 852–860

Hypertrophy Signaling Pathways in Experimental Chronic Aortic Regurgitation

  • Niels Thue Olsen
  • Veronica L. Dimaano
  • Thomas Fritz-Hansen
  • Peter Sogaard
  • Khalid Chakir
  • Kristian Eskesen
  • Charles Steenbergen
  • David A. Kass
  • Theodore P. Abraham


The development of left ventricular hypertrophy and dysfunction in aortic regurgitation (AR) has only been sparsely studied experimentally. In a new model of chronic AR in rats, we examined activation of molecular pathways involved in myocardial hypertrophy. Chronic AR was produced by damaging one or two valve cusps, resulting in eccentric remodeling and left ventricular dysfunction, with no increase in overall fibrosis. Western blotting showed increased activation of Akt and p38 at 12 weeks and of c-Jun amino-terminal kinase at 2 weeks, decreased activation of extracellular regulated kinase 5 at both 2 and 12 weeks, while activation of calcium/calmodulin-dependent protein kinase II and extracellular regulated kinase 1/2 was unchanged. Expression of calcineurin and ANF was also unchanged. Eccentric hypertrophy and early cardiac dysfunction in experimental AR are associated with a pattern of activation of intracellular pathways different from that seen with pathological hypertrophy in pressure overload, and more similar to that associated with benign physiological hypertrophy.


Aortic valve regurgitation Animal models of human disease remodeling Hypertrophy Ventricular function Proteins 


  1. 1.
    Mudd, J. O., & Kass, D. A. (2008). Tackling heart failure in the twenty-first century. Nature, 451(7181), 919–928.PubMedCrossRefGoogle Scholar
  2. 2.
    Bernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen, J. R. (2010). Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacology & Therapeutics, 128(1), 191–227.CrossRefGoogle Scholar
  3. 3.
    Plante, E., Gaudreau, M., Lachance, D., Drolet, M. C., Roussel, E., Gauthier, C., et al. (2004). Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation. Canadian Journal of Physiology and Pharmacology, 82(3), 191–199.PubMedCrossRefGoogle Scholar
  4. 4.
    Plante, E., Lachance, D., Gaudreau, M., Drolet, M. C., Roussel, E., Arsenault, M., et al. (2004). Effectiveness of beta-blockade in experimental chronic aortic regurgitation. Circulation, 110(11), 1477–1483.PubMedCrossRefGoogle Scholar
  5. 5.
    Evangelista, A., Tornos, P., Sambola, A., Permanyer-Miralda, G., & Soler-Soler, J. (2005). Long-term vasodilator therapy in patients with severe aortic regurgitation. The New England Journal of Medicine, 353(13), 1342–1349.PubMedCrossRefGoogle Scholar
  6. 6.
    Miyamoto, T., Takeishi, Y., Takahashi, H., Shishido, T., Arimoto, T., Tomoike, H., et al. (2004). Activation of distinct signal transduction pathways in hypertrophied hearts by pressure and volume overload. Basic Research in Cardiology, 99(5), 328–337.PubMedCrossRefGoogle Scholar
  7. 7.
    Toischer, K., Rokita, A. G., Unsold, B., Zhu, W., Kararigas, G., Sossalla, S., et al. (2010). Differential cardiac remodeling in preload versus afterload. Circulation, 122(10), 993–1003.PubMedCrossRefGoogle Scholar
  8. 8.
    Bekeredjian, R., & Grayburn, P. A. (2005). Valvular heart disease: aortic regurgitation. Circulation, 112(1), 125–134.PubMedCrossRefGoogle Scholar
  9. 9.
    Arsenault, M., Plante, E., Drolet, M. C., & Couet, J. (2002). Experimental aortic regurgitation in rats under echocardiographic guidance. The Journal of Heart Valve Disease, 11(1), 128–134.PubMedGoogle Scholar
  10. 10.
    Yin, F. C. (1981). Ventricular wall stress. Circulation Research, 49(4), 829–842.PubMedCrossRefGoogle Scholar
  11. 11.
    Sullivan, L. M. (2008). Repeated measures. Circulation, 117(9), 1238–1243.PubMedCrossRefGoogle Scholar
  12. 12.
    Abassi, Z., Goltsman, I., Karram, T., Winaver, J., & Hoffman, A. (2011). Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy. Journal of Biomedicine and Biotechnology, 2011, 729497.PubMedCrossRefGoogle Scholar
  13. 13.
    Uematsu, T., Yamazaki, T., Matsuno, H., Hayashi, Y., & Nakashima, M. (1989). A simple method for producing graded aortic insufficiencies in rats and subsequent development of cardiac hypertrophy. Journal of Pharmacological Methods, 22(4), 249–257.PubMedCrossRefGoogle Scholar
  14. 14.
    Magid, N. M., Opio, G., Wallerson, D. C., Young, M. S., & Borer, J. S. (1994). Heart failure due to chronic experimental aortic regurgitation. The American Journal of Physiology, 267(2 Pt 2), H556–H562.PubMedGoogle Scholar
  15. 15.
    Borer, J. S., Truter, S., Herrold, E. M., Falcone, D. J., Pena, M., Carter, J. N., et al. (2002). Myocardial fibrosis in chronic aortic regurgitation: molecular and cellular responses to volume overload. Circulation, 105(15), 1837–1842.PubMedCrossRefGoogle Scholar
  16. 16.
    Truter, S. L., Catanzaro, D. F., Supino, P. G., Gupta, A., Carter, J., Ene, A. R., et al. (2009). Fibronectin gene expression in aortic regurgitation: relative roles of mitogen-activated protein kinases. Cardiology, 113(4), 291–298.PubMedCrossRefGoogle Scholar
  17. 17.
    Truter, S. L., Catanzaro, D. F., Supino, P. G., Gupta, A., Carter, J., Herrold, E. M., et al. (2009). Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts. Cardiology, 113(3), 161–168.PubMedCrossRefGoogle Scholar
  18. 18.
    Magid, N. M., Wallerson, D. C., Borer, J. S., Mukherjee, A., Young, M. S., Devereux, R. B., et al. (1992). Left ventricular diastolic and systolic performance during chronic experimental aortic regurgitation. The American Journal of Physiology, 263(1 Pt 2), H226–H233.PubMedGoogle Scholar
  19. 19.
    Florenzano, F., & Glantz, S. A. (1987). Left ventricular mechanical adaptation to chronic aortic regurgitation in intact dogs. The American Journal of Physiology, 252(5 Pt 2), H969–H984.PubMedGoogle Scholar
  20. 20.
    Gaynor, J. W., Feneley, M. P., Gall, S. A., Jr., Savitt, M. A., Silvestry, S. C., Davis, J. W., et al. (1997). Left ventricular adaptation to aortic regurgitation in conscious dogs. The Journal of Thoracic and Cardiovascular Surgery, 113(1), 149–158.PubMedCrossRefGoogle Scholar
  21. 21.
    Olsen, N. T., Sogaard, P., Larsson, H. B., Goetze, J. P., Jons, C., Mogelvang, R., et al. (2011). Speckle-tracking echocardiography for predicting outcome in chronic aortic regurgitation during conservative management and after surgery. JACC Cardiovascular Imaging, 4(3), 223–230.PubMedCrossRefGoogle Scholar
  22. 22.
    Shioi, T., McMullen, J. R., Kang, P. M., Douglas, P. S., Obata, T., Franke, T. F., et al. (2002). Akt/protein kinase B promotes organ growth in transgenic mice. Molecular and Cellular Biology, 22(8), 2799–2809.PubMedCrossRefGoogle Scholar
  23. 23.
    McMullen, J. R., Shioi, T., Huang, W. Y., Zhang, L., Tarnavski, O., Bisping, E., et al. (2004). The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. The Journal of Biological Chemistry, 279(6), 4782–4793.PubMedCrossRefGoogle Scholar
  24. 24.
    McMullen, J. R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M. C., Kang, P. M., et al. (2003). Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 100(21), 12355–12360.PubMedCrossRefGoogle Scholar
  25. 25.
    DeBosch, B., Treskov, I., Lupu, T. S., Weinheimer, C., Kovacs, A., Courtois, M., et al. (2006). Akt1 is required for physiological cardiac growth. Circulation, 113(17), 2097–2104.PubMedCrossRefGoogle Scholar
  26. 26.
    McMullen, J. R., Amirahmadi, F., Woodcock, E. A., Schinke-Braun, M., Bouwman, R. D., Hewitt, K. A., et al. (2007). Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America, 104(2), 612–617.PubMedCrossRefGoogle Scholar
  27. 27.
    Bouchard-Thomassin, A. A., Lachance, D., Drolet, M. C., Couet, J., & Arsenault, M. (2011). A high-fructose diet worsens eccentric left ventricular hypertrophy in experimental volume overload. American Journal of Physiology. Heart and Circulatory Physiology, 300(1), H125–H134.PubMedCrossRefGoogle Scholar
  28. 28.
    Shimoyama, M., Hayashi, D., Takimoto, E., Zou, Y., Oka, T., Uozumi, H., et al. (1999). Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation, 100(24), 2449–2454.PubMedCrossRefGoogle Scholar
  29. 29.
    Lim, H. W., De Windt, L. J., Steinberg, L., Taigen, T., Witt, S. A., Kimball, T. R., et al. (2000). Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation, 101(20), 2431–2437.PubMedCrossRefGoogle Scholar
  30. 30.
    Braun, M. U., LaRosée, P., Simonis, G., Borst, M. M., & Strasser, R. H. (2004). Regulation of protein kinase C isozymes in volume overload cardiac hypertrophy. Molecular and Cellular Biochemistry, 262(1), 135–143.PubMedCrossRefGoogle Scholar
  31. 31.
    Zhang, R., Khoo, M. S., Wu, Y., Yang, Y., Grueter, C. E., Ni, G., et al. (2005). Calmodulin kinase II inhibition protects against structural heart disease. Nature Medicine, 11(4), 409–417.PubMedCrossRefGoogle Scholar
  32. 32.
    Backs, J., Backs, T., Neef, S., Kreusser, M. M., Lehmann, L. H., Patrick, D. M., et al. (2009). The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proceedings of the National Academy of Sciences of the United States of America, 106(7), 2342–2347.PubMedCrossRefGoogle Scholar
  33. 33.
    Rose, B. A., Force, T., & Wang, Y. (2010). Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiological Reviews, 90(4), 1507–1546.PubMedCrossRefGoogle Scholar
  34. 34.
    Nicol, R. L., Frey, N., Pearson, G., Cobb, M., Richardson, J., & Olson, E. N. (2001). Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. The EMBO Journal, 20(11), 2757–2767.PubMedCrossRefGoogle Scholar
  35. 35.
    Lachance, D., Plante, E., Roussel, E., Drolet, M. C., Couet, J., & Arsenault, M. (2008). Early left ventricular remodeling in acute severe aortic regurgitation: insights from an animal model. The Journal of Heart Valve Disease, 17(3), 300–308.PubMedGoogle Scholar
  36. 36.
    Kehat, I., Davis, J., Tiburcy, M., Accornero, F., Saba-El-Leil, M. K., Maillet, M., et al. (2011). Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circulation Research, 108(2), 176–183.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Niels Thue Olsen
    • 1
    • 2
  • Veronica L. Dimaano
    • 1
  • Thomas Fritz-Hansen
    • 2
  • Peter Sogaard
    • 3
  • Khalid Chakir
    • 1
  • Kristian Eskesen
    • 1
    • 2
  • Charles Steenbergen
    • 1
  • David A. Kass
    • 1
  • Theodore P. Abraham
    • 1
  1. 1.Division of CardiologyJohns Hopkins Medical InstitutionsBaltimoreUSA
  2. 2.Department of CardiologyGentofte University HospitalCopenhagenDenmark
  3. 3.Faculty of Health SciencesAalborg UniversityAalborgDenmark

Personalised recommendations